ReviewJournal of autoimmunity2019
Systemic lupus erythematosus: Diagnosis and clinical management.
Review in Journal of autoimmunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05179018 (Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus), which is not on this map. Cited by 367 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus: Case Control Study
Who cites it
367 citing papers in PubMed, 6 syntheses or guidelines pooled it, 740 citations in OpenAlex.
- Cutaneous efficacy and glucocorticoid-sparing effects of anifrolumab in systemic lupus erythematosus: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Circulating MiRNAs as diagnostic biomarkers of lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Graft survival and mortality outcomes after kidney transplant in patients with lupus nephritis: a systematic review and meta-analysis.Renal failure · 2024Pooled it
- Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature.Rheumatology international · 2024Pooled it
- Prevalence of oral mucosal lesions in patients with systemic Lupus Erythematosus: a systematic review and meta-analysis.BMC oral health · 2023Pooled it
- Systemic lupus erythematosus and prostate cancer risk: a pool of cohort studies and Mendelian randomization analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.Annals of the rheumatic diseases · 2024Trial
- Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.RMD open · 2023Trial
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- Childhood trauma and systemic lupus erythematosus activity in Tunisian patients: exploring the mediating role of post-traumatic stress disorder.Lupus science & medicine · 2026Article
- The microvascular footprint of lupus: nailfold capillaroscopy findings in Egyptian SLE patients and their link to disease activity, autoantibodies, and digital ischemia.Clinical rheumatology · 2026Article
- Machine learning models identify prognostic factors in systemic lupus erythematosus patients with epstein-barr virus infection.Clinical rheumatology · 2026Article
- Crotonylome profiling identifies MLKL crotonylation in lupus nephritis associated with RAB1A-mTOR signalling and autophagy changes in tubular epithelial cells.Lupus science & medicine · 2026Article
- Decoding Lupus Diagnosis, Pathogenesis and Therapy: From Systemic Autoimmunity to Renal Damage.Diagnostics (Basel, Switzerland) · 2026Review
- Dietary and Nutritional Factors in Systemic Lupus Erythematosus Pathophysiology: A Scoping Review of the Evidence from In Vitro, In Vivo, and Human Studies.Advances in nutrition (Bethesda, Md.) · 2026Article
- Lupus nephritis and kidney transplantation: A narrative review of patient and graft outcomes.World journal of nephrology · 2026Review
- Stress exposure prior to diagnosis and clinical characteristics in systemic lupus erythematosus: a cross-sectional study.Rheumatology international · 2026Article
- Dermatomyositis does not adversely affect functional outcomes after total hip arthroplasty: a 1:2 matched case-control study.Arthroplasty (London, England) · 2026Article
- Familial clustering and physiological risk factors associated with intervertebral disc degeneration in a large population-based cohort.Osteoarthritis and cartilage open · 2026Article
- Association of FKBP4 gene polymorphisms with glucocorticoid efficacy in pediatric systemic lupus erythematosus.Pediatric rheumatology online journal · 2026Article
307 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Systemic lupus erythematosus (SLE) is a worldwide chronic autoimmune disease which may affect every organ and tissue. Genetic predisposition, environmental triggers, and the hormonal milieu, interplay in disease development and activity. Clinical manifestations and the pattern of organ involvement are widely heterogenous, reflecting the complex mosaic of disrupted molecular pathways converging into the SLE clinical phenotype. The SLE complex pathogenesis involves multiple cellular components of the innate and immune systems, presence of autoantibodies and immunocomplexes, engagement of the complement system, dysregulation of several cytokines including type I interferons, and disruption of the clearance of nucleic acids after cell death. Use of immunomodulators and immunosuppression has altered the natural course of SLE. In addition, morbidity and mortality in SLE not only derive from direct immune mediated tissue damage but also from SLE and treatment associated complications such as accelerated coronary artery disease and increased infection risk. Here, we review the diagnostic approach as well as the etiopathogenetic rationale and clinical evidence for the management of SLE. This includes 1) lifestyle changes such as avoidance of ultraviolet light; 2) prevention of comorbidities including coronary artery disease, osteoporosis, infections, and drug toxicities; 3) use of immunomodulators (i.e. hydroxychloroquine and vitamin D); and 4) immunosuppressants and targeted therapy. We also review new upcoming agents and regimens currently under study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.